Lantern PharmaLTRN
About: Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
Employees: 21
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
700% more call options, than puts
Call options by funds: $16K | Put options by funds: $2K
63% more capital invested
Capital invested by funds: $4.9M [Q3] → $8M (+$3.09M) [Q4]
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
10.76% more ownership
Funds ownership: 12.4% [Q3] → 23.17% (+10.76%) [Q4]
3% more funds holding
Funds holding: 31 [Q3] → 32 (+1) [Q4]
20% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 10
Research analyst outlook
We haven’t received any recent analyst ratings for LTRN.
Financial journalist opinion









